All News
Filter News
Found 22,135 articles
-
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING
3/28/2024
Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor.
-
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
3/28/2024
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") today announced that on March 27, 2024 the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the supplemental Biologics License Application (sBLA) for enfortumab vedotin with KEYTRUDA® (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
-
Pharmaceutical Market Size to Hit Around USD 2,832.66 Bn by 2033
3/28/2024
According to Vision Research Reports, the global pharmaceutical market size was estimated at USD 1,559.53 billion in 2023 and it is expected to surpass around USD 2,832.66 billion by 2033.
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
3/28/2024
Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults.
-
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateConference Call and Webcast Today at 4:30 p.m. ET
3/28/2024
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.
-
Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors
3/28/2024
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.
-
XORTX Announces New Clinical Advisory Board Member - March 27, 2024
3/27/2024
XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease, is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.
-
Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma
3/27/2024
Sosei Group Corporation announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held in Tokyo.
-
Nucleus RadioPharma Announces Appointment of Chris McDonald from Kite, a Gilead Company, to Board of Directors
3/27/2024
Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Chris McDonald, Global Head of Technical Operations at Kite, a Gilead Company, to its Board of Directors.
-
Merck’s Winrevair is the second PAH drug to get the FDA’s green light in the past week, following Johnson & Johnson’s Opsynvi, which won approval on Friday.
-
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®
3/26/2024
Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
-
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
3/26/2024
Protagonist Therapeutics, Inc. announced it has randomized 241 patients in the ongoing Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera as of and expects to meet the trial's 250 patient enrollment target by the end of March 2024.
-
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing
3/26/2024
Cellares, a leader in the automation of cell therapy manufacturing and the world’s first Integrated Development and Manufacturing Organization, announced the addition of Christi Shaw to its Advisory Board.
-
Psilera Welcomes Biopharma Executive Dr. Magali Haas to its Board of Directors
3/26/2024
Psilera, a leading biotechnology company developing groundbreaking therapies for hard-to-treat neurological disorders, is pleased to announce the appointment of Magali Haas, M.D., Ph.D., to its esteemed Board of Directors.
-
Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton
3/26/2024
The French pharmaceutical company, Juvisé Pharmaceuticals, announces the acquisition of global commercial rights (excluding the United States and Canada) to Ponvory® (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson Company (Johnson & Johnson). Ponvory® is indicated for the treatment of adults with active forms of relapsing multiple sclerosis (RMS); it is protected by several patents, the latest of which expires in 2035.
-
Essential Pharma and AcedrA Biopharmaceuticals sign Distribution Agreement to commercialize essential medicines in the Middle East and North Africa region
3/26/2024
Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has signed a Distribution Agreement with AcedrA BioPharmaceuticals (“AcedrA”), a leading Saudi company operating in the Middle East and North Africa region.
-
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
3/26/2024
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the year ended December 31, 2023 and provides a corporate update.
-
Johnson & Johnson’s Opsynvi has been approved by the FDA for the treatment of pulmonary arterial hypertension, combining macitentan, which cuts the risk of clinical worsening and hospitalization, while tadalafil boosts patients’ exercise capacity.
-
Type 1 diabetes researchers from across Canada sign letter of support for diabetes research to be included in the upcoming federal budget
3/25/2024
Top researchers in the field of type 1 diabetes signed an open letter in support of renewed funding for the JDRF-CIHR Partnership to Defeat diabetes through Federal Budget 2024.
-
Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE™ Platform for the Treatment of Paroxysmal Atrial Fibrillation
3/25/2024
Biosense Webster, Inc. announced the submission of the VARIPULSE™ Platform for Premarket Approval Application (PMA) to the U.S. Food & Drug Administration (FDA).